Immutep Outlines Focused Development Strategy for Efti
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Immutep Ltd has outlined its focused development strategy for eftilagimod alfa, also known as efti, targeting specific cancer types for future clinical trials. The company has identified manufacturing differences that may have impacted previous trial outcomes and has contracted a new manufacturing run at a smaller scale. Preparations for upcoming clinical trials are underway, with a targeted start date set for the second half of the upcoming calendar year, pending regulatory and design decisions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Immutep
- S&P DJI Announces September 2026 Quarterly Rebalance
- Appendix 4E & 2026 Full Year Statutory Accounts
- Immutep Quarterly Activities Report Q4 FY26
- Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
- Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
Later from Immutep
- Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
- Change to American Depositary Share Ratio
- Immutep Receives ~A$0.86 Million R&D Tax Incentive
- Immutep Receives A$2.16 million French R&D Tax Incentive
- Immutep Quarterly Activities Report and Appendix 4C
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep